ConductScience.org, home

Paper9836088

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.

Kornbluth A. Inflamm Bowel Dis, 1998. Cited by 87 papers, by iCite.

Cite this record

ConductScience Library. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. Papers, record 9836088. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9836088

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.
PubMed
Journal
Inflamm Bowel Dis
PubMed
Year
1998
PubMed
Publication types
Conference Proceedings
PubMed
Citations, by iCite
87
iCite
Relative citation ratio, by iCite
2.02
iCite
Revised in PubMed
2026-01-28
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kornbluth AA

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Crohn DiseaseMajor topic
Drug ApprovalMajor topic
Clinical Trials as Topic
Female
Humans
Infliximab
Male
Treatment Outcome
United States
United States Food and Drug Administration

Source PubMed

Download CSV of topics

Cited by47

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 87 citations.

PMIDTitleJournalYearIn PapersSource
41908154Promising TNF-α inhibitors: Targeting pathogenic TNF-α/TNFR signaling to restore Th17/Treg balance in rheumatoid arthritis.J Pharm Anal2026https://conductscience.org/library/papers/41908154PubMed
41286500Design of minibinder proteins as universal antagonists against canine and human TNFα.Commun Biol2025https://conductscience.org/library/papers/41286500PubMed
41081067Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease.Prz Gastroenterol2025https://conductscience.org/library/papers/41081067PubMed
40186719Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems.Clin Exp Med2025https://conductscience.org/library/papers/40186719PubMed
39532820Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.Drugs2025https://conductscience.org/library/papers/39532820PubMed
39439890Worldwide research trends in Crohn's disease treatment over the past 2 decades: a bibliometric analysis.Front Pharmacol2024https://conductscience.org/library/papers/39439890PubMed
39339221Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems.Pharmaceutics2024https://conductscience.org/library/papers/39339221PubMed
38639899Surgical management of duodenal crohn's disease.Langenbecks Arch Surg2024https://conductscience.org/library/papers/38639899PubMed
38534206Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development.Antibodies (Basel)2024https://conductscience.org/library/papers/38534206PubMed
38308773Perianal fistulizing Crohn's disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies.Indian J Gastroenterol2024https://conductscience.org/library/papers/38308773PubMed
38097975The long-term effect on surgery-free survival of biological compared to conventional therapy in Crohn's disease in real world-data: a retrospective study.BMC Gastroenterol2023https://conductscience.org/library/papers/38097975PubMed
37664349Paradoxical Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor-Induced Psoriasis: A Systematic Review of Pathogenesis, Clinical Presentation, and Treatment.Cureus2023https://conductscience.org/library/papers/37664349PubMed
37288326Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study.Crohns Colitis 3602023https://conductscience.org/library/papers/37288326PubMed
37274072Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease.World J Gastroenterol2023https://conductscience.org/library/papers/37274072PubMed
36836166Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy.J Clin Med2023https://conductscience.org/library/papers/36836166PubMed
36807319Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease.Med Sci Monit2023https://conductscience.org/library/papers/36807319PubMed
36704107Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy.Front Cell Infect Microbiol2022https://conductscience.org/library/papers/36704107PubMed
35508955Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia.Intest Res2022https://conductscience.org/library/papers/35508955PubMed
34948292Alterations in Kynurenine and NAD+ Salvage Pathways during the Successful Treatment of Inflammatory Bowel Disease Suggest HCAR3 and NNMT as Potential Drug Targets.Int J Mol Sci2021https://conductscience.org/library/papers/34948292PubMed
33730998Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis.BMC Gastroenterol2021https://conductscience.org/library/papers/33730998PubMed

See all 47 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9836088

GET https://conductscience.org/api/papers/v1/9836088/cited_by?page=2